Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

Executive Summary

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.

Advertisement

Related Content

Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place
New Interim CAR-T Data Support Kite’s BLA Submission Plans
Novartis Cell Therapy Unit To Close: Implications For CAR-T Could Be Big
CAR-T Update: Kite's Filing Coming Soon
Juno Picks Up A2a Receptor Via Redox Acquisition
Juno ROCKETs On Fast Clinical Hold Resolution
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097226

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel